MET and hepatocellular carcinoma: Unfortunately, in contrast to a previous study suggesting that c-MET suppression leads to augmented PDL-1 expression in HCC (77), cabozantinib treatment did not increase PDL-1 levels in HCC cell lines and the mouse HCC models examined.